Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lanifibranor. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 20/20 | 1.00 |
| ▸ | PPARD known ✓ | Q03181 | 15/20 | 1.00 |
| ▸ | PPARA known ✓ | Q07869 | 15/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanifibranor SCHEMBL29376114 | 1.00 | PPARG (1.00) | PPARGPPARDPPARA | |
| Lanifibranor SCHEMBL29368039 | 1.00 | PPARG (1.00) | PPARGPPARDPPARA | |
| SCHEMBL3527414 | 0.94 | PPARG (0.90) | PPARGPPARDPPARA | |
| Lanifibranor SCHEMBL23854630 | 0.91 | PPARG (0.84) | PPARGPPARDPPARA | |
| Lanifibranor SCHEMBL31452215 | 0.91 | PPARG (0.84) | PPARGPPARDPPARA | |
| SCHEMBL3525858 | 0.90 | PPARG (0.81) | PPARGPPARDPPARA | |
| SCHEMBL30129668 | 0.90 | PPARG (0.81) | PPARGPPARDPPARA | |
| SCHEMBL3528266 | 0.89 | PPARG (0.80) | PPARGPPARDPPARA | |
| SCHEMBL3529488 | 0.87 | PPARG (0.77) | PPARGPPARDPPARA | |
| SCHEMBL3525861 | 0.87 | PPARG (0.87) | PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019027-B1 | COMPOSITION COMPRISING EXOSOMES DERIVED FROM INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELLS FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | BREXOGEN INC (KR) | 2025-01-22 | — | — | EP | claimed |
| CN-114025776-B | Composition for preventing or treating nonalcoholic steatohepatitis comprising exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cell precursor cells | 布瑞克斯奥根株式会社 | 2024-04-12 | — | — | CN | claimed |
| US-20220233601-A1 | COMPOSITION COMPRISING EXOSOMES DERIVED FROM INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL PROGENITOR FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | BREXOGEN INC. (KR) | 2022-07-28 | — | — | US | claimed |
| EP-4019027-A1 | COMPOSITION COMPRISING EXOSOMES DERIVED FROM INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL PRECURSOR FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | Brexogen Inc. (KR) | 2022-06-29 | — | — | EP | claimed |
| CN-109316601-B | Pharmaceutical composition and use thereof | 武汉朗来科技发展有限公司 | 2021-11-09 | — | — | CN | claimed |
| WO-2021033990-A1 | COMPOSITION COMPRISING EXOSOMES DERIVED FROM INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL PRECURSOR FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | 브렉소젠 주식회사 | 2021-02-25 | — | — | WO | claimed |
| CN-106573058-B | PPAR compounds for therapeutic use in fibrotic diseases | 伊文蒂瓦公司 | 2020-05-05 | — | — | CN | claimed |
| EP-3154543-B1 | PPAR COMPOUNDS FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | INVENTIVA (FR) | 2019-08-28 | — | — | EP | claimed |
| US-10383858-B2 | PPAR compounds for use in the treatment of fibrotic diseases | INVENTIVA (FR) | 2019-08-20 | — | — | US | claimed |
| US-20180333396-A1 | PPAR COMPOUNDS FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | INVENTIVA (FR) | 2018-11-22 | — | — | US | claimed |
| US-10052311-B2 | PPAR compounds for use in the treatment of fibrotic diseases | INVENTIVA (FR) | 2018-08-21 | — | — | US | claimed |
| US-20170189383-A1 | PPAR COMPOUNDS FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | INVENTIVA (FR) | 2017-07-06 | — | — | US | claimed |
| EP-3154543-A1 | PPAR COMPOUNDS FOR USE IN THE TREATMENT OF FIBROTIC DISEASES. | INVENTIVA (FR) | 2017-04-19 | — | — | EP | claimed |
| WO-2015189401-A1 | PPAR COMPOUNDS FOR USE IN THE TREATMENT OF FIBROTIC DISEASES. | INVENTIVA (FR) | 2015-12-17 | — | — | WO | claimed |
| US-12594303-B2 | Composition comprising exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cell progenitor for prevention or treatment of non-alcoholic steatohepatitis | BREXOGEN INC. (KR) | 2026-04-07 | — | — | US | disclosed |
| EP-4651942-A1 | LANIFIBRANOR FORMULATION | Inventiva (FR) | 2025-11-26 | — | — | EP | disclosed |
| US-20250290937-A1 | Methods and monitoring of treatment with lanifibranor | INVENTIVA (FR) | 2025-09-18 | — | — | US | disclosed |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | LABORATORIES FOURNIER S.A. (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7795297-B2 | Indole compounds, method of preparing them and uses thereof | LABORATORIES FOURNIER S.A. (FR) | 2010-09-14 | — | — | US | disclosed |
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594303-B2 | Composition comprising exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cell progenitor for prevention or treatment of non-alcoholic steatohepatitis | FABP4, FABP1, EXOSC10 | PPARG 60/4885PPARD 33/4885PPARA 21/4885 |
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LIPG, GPR119, IAPP | PPARG 1018/4885PPARD 677/4885PPARA 847/4885 |
| US-20250290937-A1 | Methods and monitoring of treatment with lanifibranor | HDGF, FGF23, HGF | PPARG 754/4885PPARD 900/4885PPARA 574/4885 |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | GPR119, PPARA, PPARG | PPARG 3/4885PPARD 4/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.